MEDLINE INC. INVESTIGATION: MDLN Securities Investors Encouraged to Contact Kirby McInerney LLP About Their Rights

Kirby McInerney LLP announced an investigation into potential securities-law claims against Medline Inc.; no lawsuit has yet been filed. The release cites a June 2, 2026 FDA warning letter over CGMP violations, which knocked MDLN shares down 7.2% to $33.19, and an August 5 earnings call where management said remediation steps caused earnings loss, driving a 12.8% drop to $36.67.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.